timothy sykes logo
Oppenheimer’s Bold Forecast: Soleno Sees $80 Price Target Amid Slower Vykat XR Launch Thumbnail
ADD US ONG Google News

Oppenheimer’s Bold Forecast: Soleno Sees $80 Price Target Amid Slower Vykat XR Launch

JACK KELLOGG•UPDATED APR. 6, 2026, 9:18 AM ET
Reviewed by Ellis Hobbs Fact-checked by Matt Monaco

Soleno Therapeutics Inc.’s stocks have been trading up by 32.49 percent due to FDA designations and promising results.

Candlestick Chart

Live Update At 09:18:00 EDT: On Monday, April 06, 2026 Soleno Therapeutics Inc. stock [NASDAQ: SLNO] is trending up by 32.49%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Soleno Therapeutics faced a mix of perspectives from investors and analysts recently. With its price target now standing at $80, decreased from $110, the market has seen a steady but slight dip in the company’s shares. Stock data from March 18, 2026, reveals that while there were price fluctuations, the overall market impression suggests confidence. The recent change in stock price target does not undermine the potential for high sales figures expected in 2026, driven by Prader-Willi syndrome treatment projections.

The company, as reflected in its profitability ratios, boasts a solid gross margin of 98.6% and a profit margin of approximately 11%. Yet, it’s worth noting the ongoing high valuation with a price-to-earnings ratio of 101.26, pointing towards future earnings reliance. Soleno’s current ratio at 5.8 signifies strong liquidity, necessary for supporting future expansion. Spirited efforts in maintaining balance, illustrated by a manageable total debt to equity rate of 0.12, provide a cushion for the inevitable market turbulence.

Consequently, Soleno’s calculated steps in financial management enable it to pursue further opportunities, especially considering the lower expected launch impact of Vykat XR in the US. Financial reports highlight a commendable operating income of $34.9M, led by effective cost management and a focus on developmental expenses. Analysts affirm that the company’s strategic planning, particularly in harnessing their leading products, signifies a promising outlook for future growth.

Navigating Market Reactions

The latest news has injected a variety of dynamics into Soleno’s market landscape. Oppenheimer’s price target adjustment alongside planned European solo commercialization provides valuable insights into the market’s course. The reduction in price target seems to derive from the careful anticipation of Vykat XR’s slower market entry within the US, which undoubtedly creates a ripple effect on market sentiment. However, Soleno remains undeterred, with long-term victories anticipated in international markets like Europe.

Shareholders have expressed a measured reaction, reflective in shares dipping by merely 1%. Such minimal movement underscores enduring investor confidence, bolstered by the reaffirmed Outperform rating that helps temper concerns about immediate earnings fluctuations. This perspective is further reinforced by Soleno’s strategic outreach to institutional investors, which encourages informed discussions on viable growth trajectories.

Despite minor stock tremors, the 2026 revenue forecast continues to beam positivity. The anticipated significant progression in Prader-Willi syndrome treatment is seen as an essential contributor to the company’s future financial health. Analysts foresee this progression markedly surpassing original expectations, signaling enduring optimism for longer viability.

More Breaking News

Conclusion

Soleno Therapeutics maintains a strategic and resilient position amidst broader market challenges. While current circumstances hint at slower-than-desired product launches, they spotlight enduring long-range prospects. The observed dip in shares only slightly shades over profound optimism from earnings expectations.

In the world of trading, adaptability is key. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” This philosophy resonates with Soleno’s dual approach at addressing US market hesitancies while banking on European solo tactics, reflecting a potent growth plan. Trader meetings and sound fiscal measures underline a promising financial portfolio, poised for potential upward momentum. With determined focus, Soleno’s outlook reveals an intrepid journey towards sustained prosperity despite uncertain horizons. The sentiment is clear: traders and stakeholders align with Soleno’s aspirations, anticipating an advantageous positioning in future growth landscapes.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading SLNO

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”